Personalized medicine--the future is already here
Personalized medicine is pharmaceuticals or biological treatments paired with diagnostic tests (companion tests) that personalized the medicine in question with genetics or genetic signatures. Target-specific cancer therapeutics has remarkably improved the outcomes of patients and represents the frontline approach to treatments in oncology today. The molecular basis governing the deveLopment of colorectal cancer is well established. K-ras is one of the early key components in the development of colorectal cancer (CRC) and is involved in many signal transduction pathways of the epidermal growth factor receptor--EGFR. Both cetuximab and panitumumab, EGFR monoclonal antibodies, are approved for the treatment of colorectal cancer. Patients with mutations in oncogene K-ras are not considered candidates for those treatments. Therefore, identifying patients with K-ras mutations is critical prior to treatment selection. In Israel, cetuximab is approved as third line therapy in CRC patients and K-ras testing is required before choosing therapy. The study by Segal et at, pubLished in this issue, assessed the prevalence of molecular types of K-ras mutations in stage IV CRC patients who failed two lines of treatment. Those results revealed a pattern similar to that seen in other studies. This editorial discusses the results of this study in the context of personalized medicine and presents the need for promoting the understanding and use of personalized medicine within the Israeli healthcare system. Use of personalized medicine Leads to better health outcomes and may result in saving healthcare costs.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:150 |
|---|---|
| Enthalten in: |
Harefuah - 150(2011), 5 vom: 30. Mai, Seite 451-2, 490 |
| Sprache: |
Hebräisch |
|---|
| Beteiligte Personen: |
Abadi-Korek, Ifat [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 12.07.2011 Date Revised 01.12.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM209217421 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM209217421 | ||
| 003 | DE-627 | ||
| 005 | 20231224005359.0 | ||
| 007 | tu | ||
| 008 | 231224s2011 xx ||||| 00| ||heb c | ||
| 028 | 5 | 2 | |a pubmed24n0697.xml |
| 035 | |a (DE-627)NLM209217421 | ||
| 035 | |a (NLM)21678641 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a heb | ||
| 100 | 1 | |a Abadi-Korek, Ifat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Personalized medicine--the future is already here |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 12.07.2011 | ||
| 500 | |a Date Revised 01.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Personalized medicine is pharmaceuticals or biological treatments paired with diagnostic tests (companion tests) that personalized the medicine in question with genetics or genetic signatures. Target-specific cancer therapeutics has remarkably improved the outcomes of patients and represents the frontline approach to treatments in oncology today. The molecular basis governing the deveLopment of colorectal cancer is well established. K-ras is one of the early key components in the development of colorectal cancer (CRC) and is involved in many signal transduction pathways of the epidermal growth factor receptor--EGFR. Both cetuximab and panitumumab, EGFR monoclonal antibodies, are approved for the treatment of colorectal cancer. Patients with mutations in oncogene K-ras are not considered candidates for those treatments. Therefore, identifying patients with K-ras mutations is critical prior to treatment selection. In Israel, cetuximab is approved as third line therapy in CRC patients and K-ras testing is required before choosing therapy. The study by Segal et at, pubLished in this issue, assessed the prevalence of molecular types of K-ras mutations in stage IV CRC patients who failed two lines of treatment. Those results revealed a pattern similar to that seen in other studies. This editorial discusses the results of this study in the context of personalized medicine and presents the need for promoting the understanding and use of personalized medicine within the Israeli healthcare system. Use of personalized medicine Leads to better health outcomes and may result in saving healthcare costs | ||
| 650 | 4 | |a Editorial | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a KRAS protein, human |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a ras Proteins |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a Cetuximab |2 NLM | |
| 650 | 7 | |a PQX0D8J21J |2 NLM | |
| 700 | 1 | |a Shemer, Joshua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Harefuah |d 1946 |g 150(2011), 5 vom: 30. Mai, Seite 451-2, 490 |w (DE-627)NLM000070491 |x 0017-7768 |7 nnns |
| 773 | 1 | 8 | |g volume:150 |g year:2011 |g number:5 |g day:30 |g month:05 |g pages:451-2, 490 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 150 |j 2011 |e 5 |b 30 |c 05 |h 451-2, 490 | ||